Analysts forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will report earnings of ($0.76) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Spero Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.96). Spero Therapeutics reported earnings of ($1.59) per share in the same quarter last year, which would indicate a positive year over year growth rate of 52.2%. The firm is expected to issue its next earnings results on Monday, April 1st.
According to Zacks, analysts expect that Spero Therapeutics will report full year earnings of ($2.81) per share for the current fiscal year, with EPS estimates ranging from ($3.01) to ($2.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.35) per share, with EPS estimates ranging from ($4.08) to ($2.59). Zacks’ EPS averages are an average based on a survey of analysts that follow Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.60) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Spero Therapeutics had a negative return on equity of 52.22% and a negative net margin of 1,402.91%. The firm had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $0.66 million.
Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of Spero Therapeutics in a research report on Thursday, August 9th. Oppenheimer set a $30.00 price target on Spero Therapeutics and gave the company a “buy” rating in a research report on Friday, August 10th. Zacks Investment Research upgraded Spero Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Wednesday, August 15th. Finally, Bank of America cut shares of Spero Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $19.00 to $9.00 in a research report on Tuesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $20.70.
Shares of SPRO traded down $0.15 during midday trading on Thursday, hitting $7.02. 6,520 shares of the company traded hands, compared to its average volume of 54,306. Spero Therapeutics has a one year low of $6.98 and a one year high of $19.00. The stock has a market cap of $123.37 million and a PE ratio of -0.39.
Several hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $146,000. Bank of New York Mellon Corp increased its position in shares of Spero Therapeutics by 73.9% in the second quarter. Bank of New York Mellon Corp now owns 24,689 shares of the company’s stock worth $363,000 after purchasing an additional 10,490 shares during the last quarter. Millennium Management LLC bought a new position in shares of Spero Therapeutics in the first quarter worth approximately $163,000. Renaissance Technologies LLC bought a new position in shares of Spero Therapeutics in the third quarter worth approximately $126,000. Finally, Highland Capital Management LP bought a new position in shares of Spero Therapeutics in the third quarter worth approximately $210,000. Institutional investors own 52.93% of the company’s stock.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Featured Story: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.